Figure 2
(A) The dose–response curve of the calibrator (squares) and interassay precision profile (circles). LoQ was calculated from the precision profile function (solid line) at a CV value equal to 20%. Each point represents a mean of 16 measurements; (B) Frequency distribution of PAM (ng/mL), measured in serum in 4850 individuals (sub-cohort of the Malmö Preventive Project). The median PAM concentration and the 95% CI (dotted line) were calculated from the fitted normal distribution curve (solid line). The data failed the D’Angostino and Pearson normality test. Non-parametric Spearman correlation of PAM concentration, determined in the PAM-LIA assay, measured between matched EDTA plasma and Li-Heparin (C). The correlation between PAM concentration (in ng/mL), determined in the PAM-LIA assay, and PAM amidating activity (in µg/L*h) (D), measured as described in Kaufmann et al. 2021. n being the number of matched pairs, r representing the correlation coefficient and p-value for statistical significance. The 95% confidence interval is shown as dotted lines.
